NCT04437160View on ClinicalTrials.gov

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

PHASE2RecruitingINTERVENTIONAL

Enrollment

286

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

January 31, 2026

Study Completion Date

December 31, 2027

Conditions

Triple Negative Breast Cancer

Interventions

DRUG

Epirubicin or Pirarubicin

Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV, q21d\*4cycls

DRUG

Cyclophosphamide

Cyclophosphamide 600mg/m2 IV, q21d\*4cycls

Trial Locations (1)

100021

RECRUITING

Cancer Hospital & Institute Chinese Academy of Medical Sciences (CAMS), Beijing

All Listed Sponsors

lead

Chinese Academy of Medical Sciences

OTHER

NCT04437160 - Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy | Biotech Hunter | Biotech Hunter